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ESMO Minimum Clinical Recommendations for diagnosis, 
treatment and follow-up of acute myeloblastic leukaemia (AML) 
in adult patients
Incidence
• The crude incidence of acute myeloblastic leukaemia (AML)
in adults in Europe is 5–8 cases/100000/year. The mortality is
∼4–6 cases/100000/year.
Diagnosis
• The diagnosis of AML requires examination of peripheral blood
samples and bone marrow aspirates. Work-up should comprise
morphological examination, cytochemistry, immuno-phenotyping
and cytogenetic analysis.
Risk assessment
• Risk assessment in AML includes the patient’s age, the initial
leucocyte count, the AML subtype, karyotype data and medical
conditions in the patient’s history that may affect the feas-
ibility of intensive chemotherapy. Elderly patients (>60 years)
have an adverse prognosis and are more susceptible to treat-
ment complications. AML with the chromosomal translocations
t(15;17) (acute promyelocytic leukaemia; APL), t(8;21) and
t(16;16) (including acute myelomonocytic leukaemia with
preponderance of eosinophil granulocytes) are considered as
favourable [II, A]. An antecedent or concomitant myelo-
dysplastic syndrome or complex aberrant karyotype are adverse
prognostic factors.
• If fungal infection is suspected a thoracic CT scan and an
abdominal ultrasound or a CT scan may be performed to assess
liver, spleen, lymph nodes and kidneys for possible patho-
logical alterations. Cardiac examination including echocardio-
graphy is recommended for patients with risk factors or a history
of heart disease [A].
• In addition to haematological and chemistry tests a coagulation
screening is to be performed prior to the insertion of central
venous lines. Human leucocyte antigen (HLA) typing should
be performed on patients who are candidates for an allogeneic
bone marrow or stem cell transplant, and should include their
family members [A].
Treatment plan
• Treatment is divided into induction and consolidation chemo-
therapy. Whenever possible treatment should be planned with
a curative intent. Candidates for allogeneic stem cell transplanta-
tion should be identified early during induction. Patients with
poor performance status and considerable co-morbidity, as well
as elderly patients not eligible for curative treatment, should
receive supportive care.
• Whenever possible AML treatment should be in clinical trials
and in centres offering a multidisciplinary approach. Such
centres should provide an adequate infrastructure including a
full haematology and medical oncology service, close collabora-
tion with a bone marrow transplant unit as well as an infectious
disease unit and an adequate transfusion service.
Induction chemotherapy
• Chemotherapy should be postponed until satisfactory material
for all diagnostic tests has been harvested. Patients with exces-
sive leucocytosis at presentation may require emergency leuca-
pheresis prior to induction chemotherapy.
• Induction chemotherapy should include an anthracycline and
cytosine arabinoside [II, A]. Patients failing to respond to one
to two cycles of such treatment are considered refractory. In
addition, APL induction chemotherapy should include all-trans
retinoic acid (ATRA) [II, A].
Consolidation therapy
• Patients entering clinical and haematological remission should
receive one to several cycles of post-remission therapy [II, A].
There is no consensus on a single preferred post-remission
treatment strategy. Patients with good risk features as defined
above should receive chemotherapy only, preferably including
high-dose cytarabine. Other patients with an HLA-identical
sibling are candidates for allogeneic stem cell transplantation
in first remission [III, A]. Patients with particular poor risk
features and no donor in their family may qualify for allogeneic
transplant with an unrelated matched donor [III, A]. The role
of high-dose consolidation chemotherapy with autologous peri-
pheral stem cell support in AML is controversial. Maintenance
chemotherapy and ATRA are beneficial in APL [III, A].
Therapy of relapsed or refractory patients
• Patients in second or subsequent remission may qualify for
allogeneic transplantation with an unrelated donor. In relapsed
APL arsenic trioxide can induce remission even if patients
have become refractory to ATRA [III, B].
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Response evaluation
• Response to induction is monitored through clinical examina-
tion, serial peripheral blood counts and bone marrow aspirates.
During induction-induced aplasia a bone marrow aspirate should
be obtained to monitor for early marrow response or leukaemic
blast persistence. The usual requirements of AML remission
are a normal cellularity of the bone marrow, morphologically
normal haematopoiesis and blast levels <5% at evaluation of
bone marrow smears [B].
Follow-up
• Patients are followed clinically with haematological examina-
tion to detect early relapse. Serial bone marrow examination is
of uncertain value in remission patients without any clinical or
haematological evidence of relapse.
Note
Levels of Evidence [I–V] and Grades of Recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the expert authors and the
ESMO Faculty.
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